Volume 28, Issue 162 (7-2018)                   J Mazandaran Univ Med Sci 2018, 28(162): 25-36 | Back to browse issues page

XML Persian Abstract Print

Abstract:   (3478 Views)
Background and purpose: Solid lipid nanoparticles are in the colloid carriers. The benefits of these drug carriers are the controlled release of the drug and the protection of the drug being loaded. Spironolactone is an aldosterone antagonist and androgen receptor. Its oral bioavailability is low due to the low solubility of this drug and its slow release. Reducing particle size by increasing the level of the drug leads to increased release, higher oral bioavailability, higher particle size in contact with the dissolution medium, and increasing the dissolvability of the drug saturation.
Materials and methods: Solvent emulsification/evaporation was used to prepare spironolactone nanoparticles. For this purpose, the lipid and drug were dissolved in an appropriate organic solvent and added to the aqueous phase containing surfactant during mixing by homogenizer. After coated with chitosan, the chitosan was dissolved in dilute acid and was added to the suspension on the stirrer drop by drop.
Results: By maintaining the amount of lipid in the formulation and increasing the amount of surfactant, the particle size decreased significantly. In general, the coating of spironolactone nanoparticles with chitosan increased the particle size and their dispersion, and the zeta potential changed from a negative value to a positive value.
Conclusion: Spironolactone coated with chitosan was found to have a slower release than solid lipid nanoparticles and nanosuspension.
Full-Text [PDF 926 kb]   (1473 Downloads)    
Type of Study: Research(Original) | Subject: Pharmaceutics

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.